Medicine & Life Sciences

1. Glioblastoma 100%
2. Temozolomide 96%
3. Non-Small Cell Lung Carcinoma 57%
4. Venous Thromboembolism 51%
5. epidermal growth factor receptor VIII 49%
6. Small Cell Lung Carcinoma 47%
7. rindopepimut 44%
8. PX-866 41%
9. Neoplasms 39%
10. Survival 38%
11. tesmilifene 37%
12. L-BLP25 34%
13. Comorbidity 31%
14. Afatinib 30%
15. Large Cell Carcinoma 26%
16. Recurrence 26%
17. Therapeutics 26%
18. Neuroendocrine Carcinoma 26%
19. Lung Neoplasms 25%
20. Everolimus 25%
21. Mechanistic Target of Rapamycin Complex 1 25%
22. Drug Therapy 24%
23. Canada 23%
24. National Cancer Institute (U.S.) 23%
25. Mutation 22%
26. Endometrial Neoplasms 20%
27. Phosphatidylinositol 3-Kinases 20%
28. Liposomes 19%
29. Anticonvulsants 19%
30. Doxorubicin 18%
31. Enzymes 18%
32. Clinical Trials 17%
33. Progression-Free Survival 16%
34. Vaccines 16%
35. Breast Neoplasms 14%
36. Blood Vessels 14%
37. Immunohistochemistry 14%
38. Diarrhea 14%
39. Survival Rate 14%
40. Neoplasm Metastasis 12%
41. Anticoagulants 10%
42. Lung 10%
43. Incidence 10%
44. Renal Insufficiency 10%
45. Fatigue 9%
46. Brain 9%
47. Safety 9%
48. Radiotherapy 9%
49. Pharmacokinetics 8%
50. Thorax 8%